

(19) World Intellectual Property Organization  
International Bureau(43) International Publication Date  
3 January 2002 (03.01.2002)

PCT

(10) International Publication Number  
**WO 02/00166 A2**(51) International Patent Classification<sup>7</sup>: **A61K**

MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(21) International Application Number: **PCT/SE01/01421**(22) International Filing Date: **20 June 2001 (20.06.2001)**

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

(25) Filing Language: **English**(26) Publication Language: **English**(30) Priority Data:  
0002476-0 **30 June 2000 (30.06.2000) SE**(71) Applicant (for all designated States except US): **ASTRAZENECA AB [SE/SE]; S-151 85 Södertälje (SE).**

(72) Inventors; and

(75) Inventors/Applicants (for US only): **BERGMAN, Rolf [SE/SE]; AstraZeneca R & D Mölndal, S-431 83 Mölndal (SE). EEK, Arne [SE/SE]; AstraZeneca R & D Södertälje, S-151 85 Södertälje (SE). LINDBERG, Per [SE/SE]; AstraZeneca R & D Mölndal, S-431 83 Mölndal (SE). OLSSON, Lars-Inge [SE/SE]; AstraZeneca R & D Södertälje, S-151 85 Södertälje (SE).**(74) Agent: **ASTRAZENECA AB; Global Intellectual Property, S-151 85 Södertälje (SE).**(81) Designated States (national): **AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,****Declarations under Rule 4.17:**


— as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) for the following designations **AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG)**

— of inventorship (Rule 4.17(iv)) for US only

**Published:**

— without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: **NEW COMPOUNDS USEFUL AS ANTIBACTERIAL AGENTS****WO 02/00166 A2**

(I)

(57) Abstract: The present invention relates to novel compounds of Formula I, and pharmaceutically acceptable salts thereof, as antibacterial agents. The compounds of the present invention are nitric oxide releasing derivatives of proton pump inhibitors (NO-releasing PPIs). In further aspects, the invention relates to compounds of the invention for use in therapy; to processes for preparation of such new compounds; to pharmaceutical compositions containing at least one compound of the invention, or a pharmaceutically acceptable salt thereof, as active ingredient; and to the use of the active compounds in the manufacture of medicaments for the medical use indicated above. The invention also relates to new intermediates for use in the preparation of the novel compounds. Additionally the present invention relates to co-administration of NO-releasing PPIs with other known medicaments.

## NEW COMPOUNDS USEFUL AS ANTIBACTERIAL AGENTS

## TECHNICAL FIELD

The present invention relates to novel compounds, and pharmaceutically acceptable salts thereof, useful as antibacterial agents. The compounds of the present invention are nitric oxide releasing derivatives of proton pump inhibitors (NO-releasing PPIs). In further aspects, the invention relates to compounds of the invention for use in therapy; to processes for preparation of such new compounds; to pharmaceutical compositions containing at least one compound of the invention, as active ingredient; and to the use of the active compounds in the manufacture of medicaments for the medical use as an antibacterial agent. The invention also relates to new intermediates for the preparation of the novel compounds. Additionally, the present invention relates to co-administration of NO-releasing PPIs with other known medicaments.

## BACKGROUND ART

The compound 5-methoxy-2-[[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole, having the generic name omeprazole, as well as pharmaceutically acceptable salts thereof, are described in EP 5129. Omeprazole is the first member in a family called proton pump inhibitors. Proton pump inhibitors are effective in inhibiting gastric acid secretion, and are consequently useful as antiulcer agents and have revolutionized the treatment of gastrointestinal disorders. Omeprazole is also known from EP 414 847 to have an antibacterial effect.

Other proton pump inhibitors, such as pantoprazole, lansoprazole, rabeprazole and leminoprazole, are all substituted benzimidazoles and therefore structurally closely related to omeprazole. Unfortunately, omeprazole and other structurally related benzimidazoles suffer from chemical instability, especially in acidic and neutral media. This makes omeprazole and other structurally related benzimidazoles difficult to handle, store and formulate.

Nitric oxide (NO) is a molecule of versatility and importance in many guises. In the atmosphere it is a noxious chemical, but in the body in small and controlled doses it is extraordinary beneficial. It helps maintain blood pressure by dilating blood vessels, helps  
5 kill foreign invaders in the immune response, is a major biochemical mediator of penile erections, and is proposed to be a major biochemical component of long-term memory.

*Helicobacter pylori* is a gram-negative bacterium which colonises in the gastric mucosa in mammalian animals, including human beings. A number of different therapies have been  
10 proposed for the treatment of *Helicobacter pylori* infections, including combination therapies. The most commonly used combination therapy comprises a proton pump inhibitor in combination with one or more antibacterial compounds, such as claritromycin and/or amoxicillin, see WO93/21920.

15 In view of the vast number of human beings suffering from gastrointestinal disorders caused or mediated by bacterial infections and also in view of the fact that many bacterial strains develop a resistance to commonly used antibiotics, a continuing need exists for a safe and effective medicament having an antibacterial effect, especially for the treatment of *Helicobacter pylori* infections.

20

## SUMMARY OF THE INVENTION

It has surprisingly been found that compounds of the Formula I below, are particularly effective as antibacterial agents. The compounds of the invention are especially suitable for treatment of infections caused by *Helicobacter pylori*.

25


The compounds of the present invention are characterized as being NO-releasing proton pump inhibitor derivatives (NO-releasing PPI or NO-PPI). A NO-releasing proton pump inhibitor is a compound which upon administration to a mammal, e.g. a human being, generates nitric oxide and a proton pump inhibitor.

5

One object of the present invention is to provide novel compounds that are effective as antibacterial agents.

In one aspect, the present invention thus relates to compounds of the Formula I:

10




wherein,

R<sup>1</sup> is hydrogen or C<sub>1</sub>-C<sub>6</sub> alkyl,

15

R<sup>2</sup> is hydrogen or C<sub>1</sub>-C<sub>6</sub> alkyl,

R<sup>3</sup> is methoxy linked to the carbon atom in position 5 or linked to the carbon atom in position 6 of the benzimidazole moiety,

X is , or a single bond

Y is -(CH<sub>2</sub>)<sub>n</sub>-, -(CH<sub>2</sub>)<sub>m</sub>-O-(CH<sub>2</sub>)<sub>p</sub>-, or a single bond, and

20


m, n, and p are integers and independently selected from 1 to 10,

or a pharmaceutically acceptable salt or enantiomer thereof.

Preferred compounds of the present invention are those of formula I wherein

$R^1$  and  $R^2$  are hydrogen,

$R^3$  is methoxy linked to the carbon atom in position 5 or linked to the carbon atom in position 6 of the benzimidazole moiety,

X is , or a single bond,

Y is  $-(CH_2)_n-$ , or a single bond, and

n is an integer from 1 to 10.

Most preferred compound of the present invention is 1-nitrooxymethyl-(5-methoxy) 2-[[[(4-methoxy-3,5-dimethyl-2-pyridyl)methyl]sulfinyl]-1H-benzimidazole and 1-nitrooxymethyl-(6-methoxy)-2-[[[(4-methoxy-3,5-dimethyl-2-pyridyl)methyl]sulfinyl]-1H-benzimidazole.

Furthermore any pure enantiomer, mixture of enantiomers, and pharmaceutically acceptable salt of the compounds of the invention are within the scope of the present invention.

As used herein, the term " $C_1-C_6$  alkyl" denotes a straight or branched alkyl group having from 1 to 6 carbon atoms. Examples of said  $C_1-C_6$  alkyl includes, but is not limited to, methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl, sec-butyl, t-butyl and straight- and branched-chain pentyl and hexyl.

It should be clear for a person skilled in the art, that compounds of formula I wherein X and Y may each and independently be "a single bond" means that X and Y may each and independently be directly linked to oxygen in  $ONO_2$ .


*Preparation*

The present invention also provides the following processes A and B for the manufacture of compounds of the Formula I.

5

*Process A*

## a) Compounds of Formula II



10


(II)

wherein  $R^1$  is hydrogen or  $C_1$ - $C_6$  alkyl,

$R^2$  is hydrogen or  $C_1$ - $C_6$  alkyl, and

$R^3$  is methoxy linked to the carbon atom in position 5 or linked to the carbon atom in position 6 of the benzimidazole moiety,

15 is reacted with thionyl chloride, or any other similar reagent, in dichloromethane, or any other similar solvent, under standard conditions to give a compound of formula III



(III)

20 wherein  $R^1$  is hydrogen or  $C_1$ - $C_6$  alkyl,


$R^2$  is hydrogen or  $C_1$ - $C_6$  alkyl,

$R^3$  is methoxy linked to the carbon atom in position 5 or linked to the carbon atom in position 6 of the benzimidazole moiety, and  
 $X^1$  is halogen, such as chloride.


- 5 b) Compounds of Formula III is thereafter reacted with silver nitrate in a suitable solvent, such as acetonitrile under standard conditions to give compounds of Formula I wherein  
 $R^1$  is hydrogen or  $C_1-C_6$  alkyl,  
 $R^2$  is hydrogen or  $C_1-C_6$  alkyl,  
 $R^3$  is methoxy linked to the carbon atom in position 5 or linked to the carbon atom in  
 10 position 6 of the benzimidazole moiety, and  
 X and Y are a single bonds

### Process B

- 15 a) Compounds of Formula II



- wherein  $R^1$  is hydrogen or  $C_1-C_6$  alkyl,  
 $R^2$  is hydrogen or  $C_1-C_6$  alkyl,  
 20  $R^3$  is methoxy linked to the carbon atom in position 5 or linked to the carbon atom in position 6 of the benzimidazole moiety, and  
 is reacted with a compound of the formula IV



wherein L is -Br or -Cl,


A is -N-, -O-, or -CH<sub>2</sub>-,

B is -Br or -Cl,

5 Y is -(CH<sub>2</sub>)<sub>n</sub>-, or -(CH<sub>2</sub>)<sub>m</sub>-O-(CH<sub>2</sub>)<sub>p</sub>-, or a single bond;

m, n, and p are integers and independently selected from 1 to 10,

under standard conditions to give a compound of Formula V



10

wherein

R<sup>1</sup> is hydrogen or C<sub>1</sub>-C<sub>6</sub> alkyl,

R<sup>2</sup> is hydrogen or C<sub>1</sub>-C<sub>6</sub> alkyl,

R<sup>3</sup> is methoxy linked to the carbon atom in position 5 or linked to the carbon atom in

15 position 6 of the benzimidazole moiety,

B is -Br or -Cl,

X is , , or ,

Y is -(CH<sub>2</sub>)<sub>n</sub>-, -(CH<sub>2</sub>)<sub>m</sub>-O-(CH<sub>2</sub>)<sub>p</sub>-, or a single bond, and




m, n, and p are integers and independently selected from 1 to 10.

20

b) Compounds of Formula V is thereafter reacted with silver nitrate in a suitable solvent, such as acetonitrile under standard conditions to give compounds of Formula I wherein R<sup>1</sup> is hydrogen or C<sub>1</sub>-C<sub>6</sub> alkyl,



$R^2$  is hydrogen or  $C_1$ - $C_6$  alkyl,

X is , , or ,

Y is  $-(CH_2)_n-$ ,  $-(CH_2)_m-O-(CH_2)_p-$ , or a single bond, and  
m, n, and p are integers and independently selected from 1 to 10.

5

Compounds of Formula II may be prepared according to the procedure disclosed in WO87/02668.

### *Medical use*

10

In a further aspect, the invention relates to compounds of formula I for use in therapy, in particular for use as an antibacterial agent. The invention also provides the use of a compound of formula I in the manufacture of a medicament for use as an antibacterial agent.

15

The typical daily dose of the active substance varies within a wide range and will depend on various factors such as *e.g.* the individual requirement of each patient and the route of administration. In general, oral and parenteral dosages will be in the range of 5 to 1000 mg per day of active substance.

20

*Pharmaceutical formulations*

In yet a further aspect, the invention relates to pharmaceutical compositions containing at least one compound of the invention, or a pharmaceutically acceptable salt thereof, as  
5 active ingredient.

For clinical use, the compounds of the invention are formulated into pharmaceutical formulations for oral, rectal, parenteral or any other mode of administration. The pharmaceutical formulation contains at least one compound of the invention in  
10 combination with one or more pharmaceutically acceptable ingredients. The carrier may be in the form of a solid, semi-solid or liquid diluent, or a capsule. These pharmaceutical preparations are a further object of the invention. Usually the amount of active compounds is between 0.1–95% by weight of the preparation, preferably between 0.1–20% by weight in preparations for parenteral use and preferably between 0.1 and 50% by weight in  
15 preparations for oral administration.

In the preparation of pharmaceutical formulations containing at least one compound of the present invention in the form of dosage units for oral administration the compound selected may be mixed with solid, powdered ingredients, or another suitable ingredient, as well as  
20 with disintegrating agents and lubricating agents. The mixture is then processed into granules or pressed into tablets.

Soft gelatin capsules may be prepared with capsules containing a mixture of the active compound or compounds of the invention. Hard gelatin capsules may contain granules of  
25 the active compound. Hard gelatin capsules may also contain the active compound in combination with solid powdered ingredients.

Dosage units for rectal administration may be prepared (i) in the form of suppositories which contain the active substance mixed with a neutral fat base; (ii) in the form of a  
30 gelatin rectal capsule which contains the active substance in a mixture with suitable vehicles for gelatin rectal capsules; (iii) in the form of a ready-made micro enema; or (iv)

in the form of a dry micro enema formulation to be reconstituted in a suitable solvent just prior to administration.

Liquid preparations for oral administration may be prepared in the form of syrups or suspensions, *e.g.* solutions or suspensions containing from 0.1% to 20% by weight of the active ingredient. If desired, such liquid preparations may contain coloring agents, flavoring agents, saccharine and carboxymethyl cellulose or other thickening agent. Liquid preparations for oral administration may also be prepared in the form of a dry powder to be reconstituted with a suitable solvent prior to use.

Solutions for parenteral administration may be prepared as a solution of at least one compound of the invention in a pharmaceutically acceptable solvent, preferably in a concentration from 0.1% to 10% by weight. These solutions may also contain stabilizing ingredients and/or buffering ingredients and are dispensed into unit doses in the form of ampoules or vials. Solutions for parenteral administration may also be prepared as a dry preparation to be reconstituted with a suitable solvent extemporaneously before use.

### *Combination therapy*

The compounds according to the present invention, or any other NO-releasing PPI, can also be used in formulations, together or in combination for simultaneous, separate or sequential use, with other active ingredients, *e.g.* for the treatment or prophylaxis of conditions involving infection by *Helicobacter pylori*. Such other active ingredients may be other antibacterial agents, in particular:

- $\beta$ -lactam antibiotics such as amoxicillin, ampicillin, cephalothin, cefaclor or cefixime;
- macrolides such as erythromycin, or clarithromycin;
- tetracyclines such as tetracycline or doxycycline;
- aminoglycosides such as gentamycin, kanamycin or amikacin;
- quinolones such as norfloxacin, ciprofloxacin or enoxacin;
- others such as metronidazole, nitrofurantoin or chloramphenicol; or

- preparations containing bismuth salts such as bismuth subcitrate, bismuth subsalicylate, bismuth subcarbonate, bismuth subnitrate or bismuth subgallate;

or NSAID (non-steroidal antiinflammatory drugs) in particular:

- 5 • ibuprofen, indomethacin, diclofenac, ketorolac, naproxen, ketoprofen, mefenamic acid, flunixin, flufenamic acid, or niflumic acid.

The compounds according to the present invention, or any other NO-releasing PPI, can also be used together or in combination for simultaneous, separate or sequential use in  
10 therapy, *e.g.* for the treatment or prophylaxis of gastrointestinal disorders, with the following medicaments:

- antacids such as aluminium hydroxide, magnesium carbonate and magnesium hydroxid or alginic acid;
- 15 • H<sub>2</sub>-blockers (*e.g.* cimetidine, ranitidine);
- gastroprokinetics (*e.g.* cisapride or mosapride); or
- other antibacterial agents and NSAIDs, in particular those indicated above.


In one aspect of the present invention, the pharmaceutical combinations of the invention  
20 may be administered as a pharmaceutical formulation, which in addition to the active compounds further may include a pharmaceutically acceptable carrier or adjuvant. In a further aspect of the invention, each active compound may be administered for combination therapy by simultaneous, or separate administration in a sequential order, *i.e.* one after the other. Thus, a further aspect of the invention is a kit comprising an  
25 NO-releasing PPI in combination with any one of the drugs mentioned above, suitable for combination therapy.

*Intermediates*

A further aspect of the invention is novel intermediate compounds, which are useful in the preparation of compounds according to the present invention.


5

Thus, one object of the invention is a compound of the formula III



- 10 wherein R<sup>1</sup> is hydrogen or C<sub>1</sub>-C<sub>6</sub> alkyl,  
 R<sup>2</sup> is hydrogen or C<sub>1</sub>-C<sub>6</sub> alkyl,  
 R<sup>3</sup> is methoxy linked to the carbon atom in position 5 or linked to the carbon atom in  
 position 6 of the benzimidazole moiety, and  
 X<sup>1</sup> is halogen, such as chloride,  
 15 or any enantiomer or salt thereof.

Another object of the invention is a compound of the Formula V



wherein


$R^1$  is hydrogen or  $C_1$ - $C_6$  alkyl,

$R^2$  is hydrogen or  $C_1$ - $C_6$  alkyl,

$R^3$  is methoxy linked to the carbon atom in position 5 or linked to the carbon atom in

5 position 6 of the benzimidazole moiety,

B is  $-Br$  or  $-Cl$ ,

X is ,

Y is  $-(CH_2)_n-$ ,  $-(CH_2)_m-O-(CH_2)_p-$ , or a single bond, and

m, n, and p are integers and independently selected from 1 to 10,

10 or any enantiomer or salt thereof.

## EXAMPLES

### Example 1.1

*Synthesis of 1-Chloromethyl-(5-methoxy) and 1-chloromethyl-(6-methoxy)-2-[[4-methoxy-3,5-dimethyl-2-pyridyl)methyl]sulfinyl]-1H-benzimidazole (isomermixture 1:2)*

1-Hydroxymethyl-(5-methoxy) and 1-hydroxymethyl-(6-methoxy)-2-[[4-methoxy-3,5-dimethyl-2-pyridyl)methyl]sulfinyl]-1H-benzimidazole (isomer mixture 1:2) (2.3 g, 6 mmol) and triethyl amine (0.9 g, 8.8 mmol) were dissolved in dichloromethane (100 ml). A solution of thionyl chloride (1.2 g, 8 mmol) in dichloromethane (10 ml) was added with such a velocity that the reaction mixture refluxed gently. After 10 minutes at ambient temperature the dichloromethane was distilled off at reduced pressure and the residue was partitioned between ethyl acetate (100 ml) and water (50 ml). When separated, the organic phase was dried over sodium sulphate, filtered and concentrated at reduced pressure. The residue was chromatographed on  $SiO_2$  (ethyl acetate) and the title compound was isolated as an oil. Yield: 470 mg (1.26 mmol) 21 %.

<sup>1</sup>H-NMR (400 MHz, CDCl<sub>3</sub>, δ): 2.23, 2.25, 2.26, 3.72, 3.85, 3.87, 4.86, 4.89, 4.90, 4.94, 4.95, 4.98, 6.16, 6.17, 6.19, 6.20, 6.52, 6.55, 6.58, 6.95, 7.01, 7.42, 7.68, 8.18.

Mass (electrospray) (M+1): 394

5 **Example 1.2**

*Synthesis of 1-Nitrooxymethyl-(5-methoxy) and 1-nitrooxymethyl-(6-methoxy)-2-[[[4-methoxy-3,5-dimethyl-2-pyridyl)methyl]sulphinyl]-1H-benzimidazole (isomer mixture 1:3)*

1-Chloromethyl-(5-methoxy) and 1-chloromethyl-(6-methoxy)-2-[[[4-methoxy-3,5-  
10 dimethyl-2-pyridyl)methyl]sulphinyl]-1H-benzimidazole (isomer mixture 1:2) (470 mg, 1.26 mmol) was dissolved in acetonitrile (50 ml). Silver nitrate (240 mg, 1.4 mmol) was added and the mixture was stirred at ambient temperature for 2 h, whereupon the solvent was distilled off at reduced pressure. The residue was partitioned between ethyl acetate (50 ml) and water (50 ml). When separated, the organic phase was dried over sodium sulphate,  
15 filtered and concentrated at reduced pressure. The residue was chromatographed on SiO<sub>2</sub> (ethyl acetate/acetone 2:1) and the title compound was isolated as a solid. Yield: 95 mg (0.22 mmol) 18 %.

<sup>1</sup>H-NMR (400 MHz, CDCl<sub>3</sub>, δ): 2.21, 2.26, 3.72, 3.86, 3.90, 4.88, 4.93, 4.94, 4.99, 6.72,  
20 6.76, 6.80, 6.84, 7.02, 7.07, 7.10, 7.25, 7.45, 7.48, 7.66, 7.69, 8.12.

Mass (electrospray) (M+1): 421

*BIOLOGICAL TESTS*

Strain: *Helicobacter pylori* reference strain NCTC 11 637 (National Type Culture  
5 Collection, from Smittskyddsinstitutet in Solna, Sweden), an antibiotic  
sensitive reference strain


Substance: as prepared in Example 1.2

*Helicobacter pylori* was grown on blood agar plates, having a diameter of 90 mm, for three  
10 days under microaerophilic conditions at 37°C. The bacteria were suspended in PBS  
(phosphate buffer saline) to approximately  $10^8$  cfu/ml. Approximately 2 ml of the  
suspension was added to one agar plate and spread even on the surface of the agar.  
Overflow was removed with a syringe. Wells, like small holes, 3 mm in diameter, were  
made in the agarplate by removing agar. Three wells per plate were made.  
15 A stock solution of a compound of the present invention having the concentration 100 000  
 $\mu\text{g/ml}$  was prepared. 30  $\mu\text{l}$  of the solution was added to the wells. The plates were  
incubated for four days before they were checked for inhibition zones around the wells.



## CLAIMS

1. A compound of formula I



wherein,

$R^1$  is hydrogen or  $C_1$ - $C_6$  alkyl,

$R^2$  is hydrogen or  $C_1$ - $C_6$  alkyl,

$R^3$  is methoxy linked to the carbon atom in position 5 or linked to the carbon atom in position 6 of the benzimidazole moiety,

X is  $-\text{O}-\text{C}(=\text{O})-\text{O}-$ ,  $-\text{O}-\text{C}(=\text{O})-\text{N}-$ ,  $-\text{O}-\text{C}(=\text{O})-\text{CH}_2-$  or a single bond

Y is  $-(\text{CH}_2)_n-$ ,  $-(\text{CH}_2)_m-\text{O}-(\text{CH}_2)_p-$ , or a single bond, and

m, n, and p are integers and independently selected from 1 to 10,

or a pharmaceutically acceptable salt or enantiomer thereof.

2. A compound of formula I according to claim 1, wherein

$R^1$  and  $R^2$  are hydrogen,


$R^3$  is methoxy linked to the carbon atom in position 5 or linked to the carbon atom in position 6 of the benzimidazole moiety,

X is  $-\text{O}-\text{C}(=\text{O})-\text{CH}_2-$  or a single bond,

Y is  $-(\text{CH}_2)_n-$ , or a single bond, and

n is an integer from 1 to 10.

3. The compound of formula I according to claim 2 being 1-nitrooxymethyl-(5-methoxy)-  
2-[[[(4-methoxy-3,5-dimethyl-2-pyridyl)methyl]sulfinyl]-1H-benzimidazole or 1-  
5 nitrooxymethyl-(6-methoxy)-2-[[[(4-methoxy-3,5-dimethyl-2-pyridyl)methyl]sulfinyl]-  
1H-benzimidazole.
4. A process for the preparation of a compound of formula I according to any one of  
claims 1 to 3 comprising the step of reacting a compound of Formula III



(III)

wherein  $R^1$  is hydrogen or  $C_1$ - $C_6$  alkyl,

$R^2$  is hydrogen or  $C_1$ - $C_6$  alkyl,

$R^3$  is methoxy linked to the carbon atom in position 5 or linked to the carbon atom in  
position 6 of the benzimidazole moiety, and

$X^I$  is halogen, such as chloride.

with silver nitrate in a suitable solvent, such as acetonitrile under standard conditions  
to give compounds of Formula I wherein


$R^1$  is hydrogen or  $C_1$ - $C_6$  alkyl,

$R^2$  is hydrogen or  $C_1$ - $C_6$  alkyl,

$R^3$  is methoxy linked to the carbon atom in position 5 or linked to the carbon atom in  
position 6 of the benzimidazole moiety, and

X and Y is each and independently a single bond.

5. A process for the preparation of a compound of formula I according to any one of claims 1 to 3 comprising the step of reacting a compound of Formula V



wherein

$R^1$  is hydrogen or  $C_1$ - $C_6$  alkyl,

$R^2$  is hydrogen or  $C_1$ - $C_6$  alkyl,

$R^3$  is methoxy linked to the carbon atom in position 5 or linked to the carbon atom in position 6 of the benzimidazole moiety,

B is  $-Br$  or  $-Cl$ ,

X is  $-O-C(=O)-O-$ ,  $-O-C(=O)-N-$ , or  $-O-C(=O)-CH_2-$ ,

Y is  $-(CH_2)_n-$ ,  $-(CH_2)_m-O-(CH_2)_p-$ , or a single bond, and

m, n, and p are integers and independently selected from 1 to 10.

with silver nitrate in a suitable solvent, such as acetonitrile under standard conditions

to give compounds of Formula I wherein

$R^1$  is hydrogen or  $C_1$ - $C_6$  alkyl,


$R^2$  is hydrogen or  $C_1$ - $C_6$  alkyl,

X is  $-O-C(=O)-O-$ ,  $-O-C(=O)-N-$ , or  $-O-C(=O)-CH_2-$ ,

Y is  $-(CH_2)_n-$ ,  $-(CH_2)_m-O-(CH_2)_p-$ , or a single bond, and

m, n, and p are integers and independently selected from 1 to 10.

6. A compound of formula I according to any one of claims 1 to 3 for use in therapy.
7. A pharmaceutical formulation containing at least one compound of formula I according to any one of claims 1 to 3 as active ingredient in combination with a pharmaceutically acceptable diluent or carrier.
8. Use of a compound of formula I according to any one of claims 1 to 3 for the manufacture of a medicament for the treatment or prophylaxis of conditions involving infection by *Helicobacter pylori*.
9. A method for the treatment or prophylaxis of conditions involving infection by *Helicobacter pylori*, which comprises administering to a mammal, including humans, in need of such treatment an effective amount of a compound of formula I according to any one of claims 1 to 3.
10. A compound of the formula III




wherein  $R^1$  is hydrogen or  $C_1$ - $C_6$  alkyl,

$R^2$  is hydrogen or  $C_1$ - $C_6$  alkyl,

$R^3$  is methoxy linked to the carbon atom in position 5 or linked to the carbon atom in position 6 of the benzimidazole moiety, and

$X^1$  is halogen, such as chloride.

11. A compound of the formula V



5 wherein

$R^1$  is hydrogen or  $C_1$ - $C_6$  alkyl,

$R^2$  is hydrogen or  $C_1$ - $C_6$  alkyl,

$R^3$  is methoxy linked to the carbon atom in position 5 or linked to the carbon atom in position 6 of the benzimidazole moiety,

10 B is  $-Br$  or  $-Cl$ ,

X is  $-O-C(=O)-O-$ ,  $-O-C(=O)-N-$ , or  $-O-C(=O)-CH_2-$ ,

Y is  $-(CH_2)_n-$ ,  $-(CH_2)_m-O-(CH_2)_p-$ , or a single bond, and

m, n, and p are integers and independently selected from 1 to 10.

15 12. A pharmaceutical combination containing at least one compound of formula I according to any one of claims 1-3 and at least one other antibacterial compound in one single or separate dosage form for simultaneous, separate or sequential use in the prevention or treatment of bacterial infections, optionally together with one or more pharmaceutically acceptable diluents or carriers.

13. A pharmaceutical combination according to claim 12, wherein the at least other antibacterial compound is selected from any one of  $\beta$ -lactam antibiotics, macrolides, tetracyclines, aminoglycosides and quinolones.
- 5 14. A pharmaceutical combination containing at least one compound of formula I according to any one of claims 1-3 and at least one NSAID in one single or separate dosage form for simultaneous, separate or sequential use in the prevention or treatment of bacterial infections.
- 10 15. A pharmaceutical combination according to claim 14, wherein the NSAID is selected from any one of ibuprofen, indomethacin, diclofenac, ketorolac, naproxen, ketoprofen, mefenamic acid, flunixin, flufenamic acid and niflumic acid.
- 15 16. A pharmaceutical combination according to any one of claims 12-15, in form of a pharmaceutical formulation.
17. Use of a compound according to any one of claims 1 to 3 for the manufacture of a medicament for the treatment or prophylaxis of bacterial infections, wherein said medicament is adapted to be administered in combination with at least one other  
20 antibacterial agent.
18. Use of a compound according to any one of claims 1 to 3 for the manufacture of a medicament for the treatment or prophylaxis of bacterial infections, wherein said medicament is adapted to be administered in combination with at least one NSAID.  
25
19. Use of a NO-releasing PPI for the manufacture of a medicament for the treatment or prophylaxis of bacterial infections.

20. A pharmaceutical composition containing at least one NO-releasing PPI and at least one other antibacterial compound in one single or separate dosage forms for simultaneous, separate or sequential use in the prevention or treatment of bacterial infections.
- 5 21. A pharmaceutical composition containing at least one NO-releasing PPI and at least one NSAID in one single or separate dosage forms for simultaneous, separate or sequential use in the prevention or treatment of bacterial infections.
22. A kit comprising an NO-releasing PPI in combination with at least one antibacterial  
10 compound.
23. A kit comprising an NO-releasing PPI in combination with at least one NSAID.

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
3 January 2002 (03.01.2002)

PCT

(10) International Publication Number  
**WO 02/00167 A3**

(51) International Patent Classification<sup>7</sup>: C07C 69/76,  
219/18

WANG, Tingmin [—/US]; 585 Sonoma Street, San  
Marcos, CA 92069 (US).

(21) International Application Number: PCT/US01/19750

(74) Agents: REITER, Stephen, E. et al.; Foley & Lardner,  
23rd Floor, 402 West Broadway, San Diego, CA 92101-  
3542 (US).

(22) International Filing Date: 19 June 2001 (19.06.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
09/602,688 23 June 2000 (23.06.2000) US  
09/715,767 17 November 2000 (17.11.2000) US

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,  
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,  
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,  
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,  
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,  
MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK,  
SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA,  
ZW.

(63) Related by continuation (CON) or continuation-in-part  
(CIP) to earlier applications:

US 09/602,688 (CON)  
Filed on 23 June 2000 (23.06.2000)  
US 09/715,767 (CON)  
Filed on 17 November 2000 (17.11.2000)

(84) Designated States (*regional*): ARIPO patent (GH, GM,  
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian  
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European  
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,  
IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF,  
CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report

(71) Applicant (*for all designated States except US*): MEDI-  
NOX, INC. [US/US]; Suite 201, 11575 Sorrento Valley  
Road, San Diego, CA 92121 (US).

(88) Date of publication of the international search report:  
4 April 2002

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): LAI, Ching-San  
[US/US]; 209 Lolita Street, Encinitas, CA 92024 (US).

*For two-letter codes and other abbreviations, refer to the "Guid-  
ance Notes on Codes and Abbreviations" appearing at the begin-  
ning of each regular issue of the PCT Gazette.*

(54) Title: MODIFIED FORMS OF PHARMACOLOGICALLY ACTIVE AGENTS AND USES THEREFOR

(57) Abstract: In accordance with the present invention, there are provided modified forms of nonsteroidal anti-inflammatory drugs (NSAIDs). Modified NSAIDs according to the invention provide a new class of anti-inflammatory agent which provides the therapeutic benefits of NSAIDs while causing a much lower incidence of side-effects than typically observed with such agents.

WO 02/00167 A3





## INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US01/19750

## A. CLASSIFICATION OF SUBJECT MATTER

IPC(7) : C07C 69/76, 219/18

US CL : 560/21, 100: 514/534, 539

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 560/21, 100; 514/534, 539

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched  
Chemical Abstracts, Index Chemicals, Current Abstracts of Chemistry

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A,P	US 6,177,466 B1 (SAKAKI et al.) 23 January 2001, see entire document.	1-61

☐ Further documents are listed in the continuation of Box C.☐ See patent family annex.

* Special categories of cited documents	*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
*A* document defining the general state of the art which is not considered to be of particular relevance	*X* document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
*E* earlier document published on or after the international filing date	*Y* document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
*L* document which may throw doubts on priority claims or which is cited to establish the publication date of another citation or other special reason (as specified)	*A* document member of the same patent family
*O* document referring to an oral disclosure, use, exhibition or other means	
*P* document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

08 AUGUST 2001

Date of mailing of the international search report

27 DEC 2001

Name and mailing address of the ISA/US  
Commissioner of Patents and Trademarks  
Box PCT  
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

FLOYD D. HIGEL

Telephone No. (703) 308-1235